Placeholder Banner

BIO Announces Leadership Update

October 10, 2022
Media Contact

Today, Dr. Michelle McMurry-Heath informed the Biotechnology Innovation Organization (BIO) Executive Committee that she is stepping down from her position as President and Chief Executive Officer effective October 11, 2022, and she has agreed to instead serve as Advisor to the Executive Committee, providing advice and assistance on key BIO initiatives.

“The Board of Directors thanks Dr. McMurry-Heath for her service to BIO as CEO and appreciates her continued work with BIO in the months ahead in support of biotech innovation and the patients the organization serves,” said Paul Hastings, Chair of BIO Executive Committee & Board of Directors.

“Dr. McMurry-Heath has earned widespread admiration and recognition as a voice for the biotech industry, broadening awareness of key industry imperatives, such as supporting life-saving biotech innovation and overcoming the challenges of COVID-19, and advancing initiatives to increase diversity and inclusivity across the biotech industry,” said Ted W. Love, M.D., Vice-Chair of BIO Executive Committee & Board of Directors.

BIO will identify an interim CEO and launch a search for a successor.

Discover More
The Creating Hope Reauthorization Act of 2024 was introduced in the House of Representatives this week. BIO CEO and President, Rachel King, made the following statement following the bill's introduction: "BIO strongly supports the House…
Legislation to restore immediate R&D expensing passed the House by 357-70 yesterday. Following the vote, BIO's Chief Advocacy Officer, Nick Shipley, made the following statement:  "The bipartisan legislation passed by the U.S. House…
Yesterday, Reps. Greg Murphy, M.D. (R-NC), Don Davis (D-NC) and Brett Guthrie introduced the Ensuring Pathways to Innovative Cures (EPIC Act), legislation to fix the “pill penalty.” BIO President and CEO, Rachel King, made the following statement: …